Stewart, Duncan J. http://orcid.org/0000-0002-9113-8691
Gianchetti, Albert
Byrnes, Dawn
Dittrich, Howard C.
Thorne, Barb
Manza, Linda L.
Reinhardt, Rickey R.
Funding for this research was provided by:
D.J.S. is a scientific advisory board member of Xylocor
A.G. was a full-time employee of XyloCor Therapeutics when this work was done.
D.B. was a full-time employee of XyloCor Therapeutics when this work was done.
H.C.D. was a full-time employee of XyloCor Therapeutics when this work was done.
B.T. was a full-time employee of XyloCor Therapeutics when this work was done.
R.R.R. was a full-time employee of XyloCor Therapeutics when this work was done.
Article History
Received: 23 November 2022
Revised: 19 July 2023
Accepted: 27 July 2023
First Online: 18 August 2023
Competing interests
: AG, DB, HCD, and RRR were full-time employees of XyloCor Therapeutics when this work was done. DJS is a scientific advisory board member of XyloCor Therapeutics. The remaining authors declare no competing interests.
: Procedures involving the care or use of animals in this study were reviewed and approved by Absorption Systems California, LLC (ASC’s) Institutional Animal Care and Use Committee (IACUC) prior to the initiation of such procedures. During the study, the care and use of animals was conducted in accordance with the regulations of the USDA Animal Welfare Act (i.e., relevant sections of Section 9, Parts 1, 2, and 3, of the Code of Federal Regulations) and in compliance with ASC’s Animal Welfare Assurance (A4282-01) filed with the National Institutes of Health (NIH).